This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Dec 2;363(23):2256-7.

doi: 10.1056/NEJMe1010681. Epub 2010 Nov 17.

Taking the guesswork out of uveal melanoma

Meenhard Herlyn, Katherine L Nathanson

PMID: 21083377
DOI: 10.1056/NEJMe1010681

Editorial

Taking the guesswork out of uveal melanoma

Meenhard Herlyn et al. N Engl J Med. 2010.

. 2010 Dec 2;363(23):2256-7.

doi: 10.1056/NEJMe1010681. Epub 2010 Nov 17.

Authors

Meenhard Herlyn, Katherine L Nathanson

PMID: 21083377
DOI: 10.1056/NEJMe1010681

No abstract available

PubMed Disclaimer

Comment on

Mutations in GNA11 in uveal melanoma.
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O'Brien J, Bastian BC. Van Raamsdonk CD, et al. N Engl J Med. 2010 Dec 2;363(23):2191-9. doi: 10.1056/NEJMoa1000584. Epub 2010 Nov 17. N Engl J Med. 2010. PMID: 21083380 Free PMC article.

Similar articles

Mutations in GNA11 in uveal melanoma.
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O'Brien J, Bastian BC. Van Raamsdonk CD, et al. N Engl J Med. 2010 Dec 2;363(23):2191-9. doi: 10.1056/NEJMoa1000584. Epub 2010 Nov 17. N Engl J Med. 2010. PMID: 21083380 Free PMC article.
GNA11-mutated and BAP1-negative Melanomas Ex Blue Naevi: A Particularly Aggressive Entity.
Uguen A, Guibourg B, Costa S, Marcorelles P. Uguen A, et al. Acta Derm Venereol. 2017 Jun 9;97(6):743-744. doi: 10.2340/00015555-2594. Acta Derm Venereol. 2017. PMID: 27990554 No abstract available.
A melanoma subtype: uveal melanoma.
Wu J, Brunner G, Celebi JT. Wu J, et al. J Am Acad Dermatol. 2011 Jun;64(6):1185-6. doi: 10.1016/j.jaad.2010.06.004. J Am Acad Dermatol. 2011. PMID: 21571184 Free PMC article. No abstract available.
GNAQ and GNA11 mutations in uveal melanoma.
Shoushtari AN, Carvajal RD. Shoushtari AN, et al. Melanoma Res. 2014 Dec;24(6):525-34. doi: 10.1097/CMR.0000000000000121. Melanoma Res. 2014. PMID: 25304237 Review.
Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
Gaffal E. Gaffal E. J Dtsch Dermatol Ges. 2020 Nov;18(11):1245-1248. doi: 10.1111/ddg.14288. Epub 2020 Sep 21. J Dtsch Dermatol Ges. 2020. PMID: 32954611 Review.

See all similar articles

Cited by

BAP1 Tumour Predisposition Syndrome Due to Whole BAP1 Gene Deletion.
Pandithan D, Klebe S, McKavanagh G, Rawlings L, Yu S, Nicholl J, Poplawski N. Pandithan D, et al. Case Rep Genet. 2022 Sep 13;2022:5503505. doi: 10.1155/2022/5503505. eCollection 2022. Case Rep Genet. 2022. PMID: 36148247 Free PMC article.
Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma.
Masoomian B, Shields JA, Shields CL. Masoomian B, et al. J Curr Ophthalmol. 2018 Mar 22;30(2):102-109. doi: 10.1016/j.joco.2018.02.005. eCollection 2018 Jun. J Curr Ophthalmol. 2018. PMID: 29988936 Free PMC article. Review.
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents.
Khan MK, Khan N, Almasan A, Macklis R. Khan MK, et al. Onco Targets Ther. 2011;4:137-48. doi: 10.2147/OTT.S20257. Epub 2011 Aug 9. Onco Targets Ther. 2011. PMID: 21949607 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

R01 CA118871/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.